ArticleExperimental and therapeutic medicine2012
Beyond free radical scavenging: Beneficial effects of edaravone (Radicut) in various diseases (Review).
Article in Experimental and therapeutic medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- Adjunctive cytoprotective therapies in acute ischemic stroke: a systematic review.Fluids and barriers of the CNS · 2021Pooled it
- Evaluating the effect of Edaravone on clinical outcome of patients with severe COVID-19 admitted to ICU: a randomized clinical trial.Inflammopharmacology · 2022Trial
- Effects of Edaravone Treatment on Endometriotic Lesion Sizes in a Surgically Induced Rat Model: A Pilot Study.Drug design, development and therapy · 2026Article
- HR-MS Analysis of the Covalent Binding of Edaravone to 5-Formylpyrimidine Bases and a DNA Oligonucleotide Containing a 5-Formylcytidine Residue.Rapid communications in mass spectrometry : RCM · 2025Article
- Ameliorative effects of Edaravone against Valproic Acid-Induced kidney damage.Journal of molecular histology · 2024Article
- Sorafenib and edaravone protect against renal fibrosis induced by unilateral ureteral obstruction via inhibition of oxidative stress, inflammation, and RIPK-3/MLKL pathway.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- The protective effect of Edaravone against acute renocardiac syndrome in a kidney ischemia-reperfusion model.Journal of cardiovascular and thoracic research · 2024Article
- Article
- Edaravone Improved Behavioral Abnormalities, Alleviated Oxidative Stress Inflammation, and Metabolic Homeostasis Pathways in Depression.Depression and anxiety · 2023Article
- Synthesis of 4-Aminopyrazol-5-ols as Edaravone Analogs and Their Antioxidant Activity.Molecules (Basel, Switzerland) · 2022Article
- Mitigation of cholestasis-associated hepatic and renal injury by edaravone treatment: Evaluation of its effects on oxidative stress and mitochondrial function.Liver research (Beijing, China) · 2021Article
- Edaravone: A potential treatment for the COVID-19-induced inflammatory syndrome?Pharmacological research · 2020Article
- Evaluation of the protective effect of edaravone on doxorubicin nephrotoxicity by [Naunyn-Schmiedeberg's archives of pharmacology · 2020Article
- Acetylated Polysaccharides FromInternational journal of molecular sciences · 2020Article
- Edaravone Ameliorates Renal Warm Ischemia-Reperfusion Injury by Downregulating Endoplasmic Reticulum Stress in a Rat Resuscitation Model.Drug design, development and therapy · 2020Article
- Edaravone reduces oxidative stress and intestinal cell apoptosis after burn through up-regulating miR-320 expression.Molecular medicine (Cambridge, Mass.) · 2019Article
- Retrospective study of clinical features and prognosis of edaravone in the treatment of paraquat poisoning.Medicine · 2019Article
- Safety of intrathecal injection of Wharton's jelly-derived mesenchymal stem cells in amyotrophic lateral sclerosis therapy.Neural regeneration research · 2019Article
- Self-nanomicellizing solid dispersion of edaravone: part II: in vivo assessment of efficacy against behavior deficits and safety in Alzheimer's disease model.Drug design, development and therapy · 2018Article
- Self-nanomicellizing solid dispersion of edaravone: part I - oral bioavailability improvement.Drug design, development and therapy · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Free radicals play an important role in the pathogenesis of a variety of diseases; thus, they are an attractive target for therapeutic intervention in these diseases. Compounds capable of scavenging free radicals have been developed for this purpose and some, developed for the treatment of cerebral ischemic stroke, have progressed to clinical trials. One such scavenger, edaravone, is used to treat patients within 24 h of stroke. Edaravone, which can diffuse into many disease-affected organs, also shows protective effects in the heart, lung, intestine, liver, pancreas, kidney, bladder and testis. As well as scavenging free radicals, edaravone has anti-apoptotic, anti-necrotic and anti-cytokine effects in various diseases. Here, we critically review the literature on its clinical efficacy and examine whether edaravone should be considered a candidate for worldwide development, focusing on its effects on diseases other than cerebral infarction. Edaravone has been safely used as a free radical scavenger for more than 10 years; we propose that edaravone may offer a novel treatment option for several diseases.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.